K11014—Pathology

Contact:

Mentor: Zdenek Hel, Ph.D. Assistant Professor Mailing address: 845 19th Street South, BBRB 730, Birmingham, AL 35294-2170; Telephone: (205) 975-7079; E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it. .  


A postdoctoral position is available in the laboratory of Dr. Zdenek Hel in the Department of Pathology. The laboratory focuses on various aspects of HIV-1 pathogenesis including dysregulation of antibody and cellular immune responses and testing of novel approaches of HIV-1 prevention using studies in humans and animal models. In addition, we focus on the design of novel approaches to cancer immunotherapy. We are looking for highly motivated individuals interested in viral and cancer immunology, HIV-1 pathogenesis, and prevention research. Experience in immunology and molecular biology is desirable. The University of Alabama at Birmingham ranks among the Top 16 Biomedical Research Institutions in the nation in funding from the National Institute of Health (NIH). The Department of Pathology has been ranked among the top ten in research funding from NIH.

To apply: Send a letter of intent describing research accomplishments and plans, CV, and the names and contact information of three references to Dr. Zdenek Hel at This email address is being protected from spambots. You need JavaScript enabled to view it. .  

UAB News

  • As kids prepare to head back to school, required immunizations are typically on the to-do list, but getting potentially lifesaving vaccines should not end when adulthood begins, says one University of Alabama at Birmingham infectious diseases expert.

  • effrey R. Curtis, M.D., from the University of Alabama at Birmingham, and colleagues utilized 1998 to 2011 data from the U.S. Veterans Health Administration to identify RA patients initiating rituximab, abatacept, or anti-tumor necrosis factor (anti-TNF) therapy. The authors sought to assess the comparative risk of hospitalized infection associated with anti-TNF and non-anti-TNF biologic agents.

UAB Research News

  • New drugs to slow or even prevent Parkinson’s could be in human studies as early as 2015.Written by Matt Windsor An enzyme closely associated with genetic forms of Parkinson’s disease appears to play a larger role in its progression than previously thought, say investigators at the University of Alabama at Birmingham. The new research offers encouraging evidence that drugs to block this enzyme, known as leucine-rich repeat kinase 2 or LRRK2, could slow — or even...

  • UAB School of Nursing's federally funded study shows both the patient and caregiver benefit from early palliative care.The earlier a specific phone-based, palliative care support program can be introduced to caregivers, the better they will be able to cope with the caregiving experience, according to research conducted by University of Alabama at Birmingham School of Nursing investigators. The patient outcomes from the study, known as ENABLE III, were presented June 3 at the American Society of...